Some hailed 2023 as the start of a turning level in our efforts to fight Alzheimer’s illness. Two international locations – the US and Japan – authorized a drug referred to as lecanemab, the primary therapy that really slows the situation’s development, moderately than simply easing its signs. Many different international locations, together with the UK and Australia, at the moment are contemplating following swimsuit, however the drug isn’t with out its critics.

Lecanemab gained approval in…